Launch relatlimab plus nivolumab, mavacamten, and deucravacitinib
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- by 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib.”
What we found
Evidence strength A What the grades mean
Bristol Myers Squibb successfully launched all three first-in-class medicines—relatlimab plus nivolumab (Opdualag), mavacamten (Camzyos), and deucravacitinib (Sotyktu)—during 2022.
-
A Bristol Myers Squibb Co. 8-K filed 2023-02-02
“We are especially proud to have launched three first-in-class medicines that address serious unmet medical needs for patients.” ✓ confirmed on the page
-
A Bristol Myers Squibb Co. 10-K filed 2023-02-14
“Camzyos (mavacamten)Obstructive HCMOctober 2022 Announced that the FDA accepted the supplemental NDA for Camzyos” ✓ confirmed on the page
-
A Bristol Myers Squibb Co. 10-Q filed 2023-04-27
“Opdualag was launched in March 2022.” ✓ confirmed on the page
Market reaction: the shares moved +4.9% against the S&P 500 over the three sessions around the disclosure (1 Feb 2023 to 6 Feb 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- relatlimab plus nivolumab, mavacamten, and deucravacitinib
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-BMY-004353 · Corrections policy